Many staff members will ask you to say and spell your name and birth date
SUMMIT: Tirzepatide and heart failure with preserved ejection fraction SUMMIT (Packer et al., NEJM 2024, NEJMoa2410027, PMID 39555826) randomized 731 patients with heart failure with preserved ejection fraction (HFpEF) and a BMI 30 to tirzepatide up to 15 mg/week or placebo, with a median follow-up of 104 weeks
Healthcare providers can assess whether symptoms represent normal adjustment to semaglutide or indicate a need for dose modification, temporary discontinuation, or investigation for alternative diagnoses
Perspective from the study authors GLP-1 medications have already changed the way physicians treat type 2 diabetes and obesity, but little real-world data exist to compare the effectiveness of the two most common medications, Ozempic and Mounjaro
Can I switch from another GLP-1 (Wegovy, Ozempic) to Zepbound